Your browser doesn't support javascript.

BVS APS

Atenção Primária à Saúde

Home > Pesquisa > ()
XML
Imprimir Exportar

Formato de exportação:

Exportar

Email
Adicionar mais destinatários
| |

Costo-efectividad de la vacuna tetravalente contra VPH en Argentina, a partir de un modelo dinámico de transmisión. / [Cost-effectiveness of quadrivalent vaccine against human papilloma virus in Argentina based on a dynamic transmission model].

Pichon-Riviere, Andrés; Alcaraz, Andrea; Caporale, Joaquín; Bardach, Ariel; Rey-Ares, Lucila; Klein, Karen; Calderón, María; Augustovski, Federico; Tatti, Silvio.
Salud Publica Mex; 57(6): 504-13, 2015 Nov-Dec.
Artigo em Espanhol | MEDLINE | Dez 2015 | ID: mdl-26679313
Resumo: OBJECTIVE: To assess the cost-effectiveness of the quadrivalent vaccine against human papillomavirus (HPV) in Argentina from the health system perspective. MATERIALS AND METHODS: A dynamic transmission model was used to estimate the impact of the vaccine on the incidence of cervical cancer, warts, and other HPV related diseases; in quality adjusted life years (QALYs); and in healthcare costs. RESULTS: Vaccination could reduce the risk of cervical cancer by 60% and by 67% the risk of genital warts. Compared to a non-vaccine scenario, the immunization strategy showed an incremental benefit of 0.00234 QALY per person at an incremental cost of US$2.36, resulting in an incremental cost-effectiveness ratio of US$1007.55 per QALY gained. Sensitivity analysis proved the robustness of these results. CONCLUSIONS: Immunization with the quadrivalent vaccine was a cost-effective intervention in Argentina, and it was far below the threshold of one gross domestic product per capita (US$15 009) per QALY gained.